Alto Neuroscience Emerges with Largest Clinical-Stage Precision Psychiatry Pipeline and $40 Million in Financing
Summary
Alto’s platform evolved out of more than a decade of clinical neuroscience research from the distinguished Etkin Lab at Stanford University and has since been validated by numerous publications in high-impact, peer-reviewed academic journals. Recognizing the therapeutic potential of these findings, Dr. Etkin is departing a tenured professorship at Stanford to continue leading Alto with the goal of revolutionizing the diagnosis and treatment of mental health conditions. “For years, I personally witnessed the limitations of existing mental health treatments and lack of innovation in the space when caring for my own patients,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto. Historically, clinical trial design has not adequately accounted for these differences, contributing to a persistent lack of innovation and fundamental failures in psychiatric drug development. Its artificial intelligence (AI)-enabled platform measures biomarkers like EEG and wearable data, behavioral patterns, genetics and other factors, to match patients with the treatment they are most likely to respond to.